Eris Lifesciences has announced a conference call for analysts and investors to discuss the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The meeting is scheduled for Wednesday, May 20, 2026, at 4:30 PM IST, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

Earnings Call Details

The company has provided the following specifics for the upcoming earnings call:

Participants are required to pre-register using the provided link to join the session. The company looks forward to the participation of analysts and investors.

Board Meeting Context

This conference call follows the intimation of a Board of Directors meeting scheduled for the same date. The board is convened to consider and approve the audited financial results for the fourth quarter and financial year ended March 31, 2026, as well as to consider the declaration of an interim dividend for the financial year 2026-27.

Trading Window Closure

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons and their immediate relatives remains closed. The window, effective from April 01, 2026, will reopen 48 hours after the declaration of the financial results.

Eris Lifesciences announced the allotment of 24,396 equity shares on May 11, 2026, pursuant to the exercise of stock options under its ESOP-2021 Scheme. The allotment was formally communicated to both BSE Limited and the National Stock Exchange of India Limited by Milind Talegaonkar, Company Secretary and Compliance Officer.

ESOP-2021 Scheme Allotment Details

The allotment under the ESOP-2021 Scheme spans three grant years, with varying issue prices per share for each year. The following table provides a breakdown of the shares allotted and the corresponding issue prices:

The total of 24,396 equity shares allotted on May 11, 2026 reflects the cumulative exercise of options across these three grant years under the ESOP-2021 Scheme.

Impact on Paid-Up Share Capital

Following the allotment, the paid-up share capital of Eris Lifesciences has been revised upward. Each equity share carries a face value of ₹1. The table below summarises the change in paid-up share capital:

The disclosure was made in compliance with applicable listing obligations, and the information has been submitted for record with both stock exchanges. The communication was signed by Milind Talegaonkar, Company Secretary and Compliance Officer, bearing ICSI Membership No. A26493, with a digital signature dated May 11, 2026.